OXPHOS dysfunction regulates integrin- beta 1 modifications and enhances cell motility and migration

• Published in: Human molecular genetics Vol. 24; no. 7; pp. 1977 - 1990
• Main Authors: Nunes, Joana B, Peixoto, Joana, Soares, Paula, Maximo, Valdemar, Carvalho, Sandra, Pinho, Salome S, Vieira, Andre F, Paredes, Joana, Rego, Ana C, Ferreira, Ildete L, Gomez-Lazaro, Maria, Sobrinho-Simoes, Manuel, Singh, Keshav K, Lima, Jorge
• Format: Journal Article
• Language: English
• Published: 01.04.2015
• ISSN: 0964-6906; 1460-2083
• DOI: 10.1093/hmg/ddu612

Mitochondria are central organelles for cellular metabolism. In cancer cells, mitochondrial oxidative phosphorylation (OXPHOS) dysfunction has been shown to promote migration, invasion, metastization and apoptosis resistance. With the purpose of analysing the effects of OXPHOS dysfunction in cancer cells and the molecular players involved, we generated cybrid cell lines harbouring either wild-type (WT) or mutant mitochondrial DNA (mtDNA) [tRNAmut cybrids, which harbour the pathogenic A3243T mutation in the leucine transfer RNA gene (tRNAleu)]. tRNAmut cybrids exhibited lower oxygen consumption and higher glucose consumption and lactate production than WT cybrids. tRNAmut cybrids displayed increased motility and migration capacities, which were associated with altered integrin- beta 1 N-glycosylation, in particular with higher levels of beta -1,6-N-acetylglucosamine (GlcNAc) branched N-glycans. This integrin- beta 1 N-glycosylation pattern was correlated with higher levels of membrane-bound integrin- beta 1 and also with increased binding to fibronectin. When cultured in vitro, tRNAmut cybrids presented lower growth rate than WT cybrids, however, when injected in nude mice, tRNAmut cybrids produced larger tumours and showed higher metastatic potential than WT cybrids. We conclude that mtDNA-driven OXPHOS dysfunction correlates with increased motility and migration capacities, through a mechanism that may involve the cross talk between cancer cell mitochondria and the extracellular matrix.